|
1) Acs G, Sells MA, Purcell RH, et al. Hepatitis B virus produced by transfected HepG2 cells causes hepatitis in chimpanzees. Proc Natl Acad Sci USA. 1987; 84: 4641-4
|
|
|
|
|
2) Takahashi H, Fujimoto J, Hanada S, et al. Isselbacher, Acute hepatitis in rats expressing human hepatitis B virus transgenes. Proc Natl Acad Sci USA. 1995; 92: 1470-4
|
|
|
|
|
|
3) Suzuki T, Takehara T, Ohkawa K, et al. Intravenous injection of naked plasmid DNA encoding hepatitis B virus (HBV) produces HBV and induces humoral immune response in mice. BBRC. 2003; 300: 784-8
|
|
|
|
|
|
4) Yang PL, Althage A, Chung J, et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA. 2002; 99: 13825-30
|
|
|
|
|
|
5) Tsuge M, Hiraga N, Takaishi H, et al. Infection of human hepatocyte chimeric mouse with genetically engeneered hepatitis B virus. Hepatology. 2005; 42: 1046-54
|
|
|
|
|
6) Hiraga M, Imamura M, Tsuge T, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Letts. 2007; 581: 1983-7
|
|
|
|
|
|
7) Heckel JL, Sandgren EP, Degen JL, et al. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell. 1990; 62: 447-56
|
|
|
|
|
|
8) Rhim JA, Sandgren EP, Degen JL, et al. Replacement of diseased mouse liver hepatic cell transplantation. Science. 1994; 263: 1149-52
|
|
|
|
|
|
9) Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol. 2004; 165: 901-12
|
|
|
|
|
|
10) Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology. 2001; 33: 981-8
|
|
|
|
|
|
11) Meuleman P, Libbrecht L, Wieland S, et al. Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol. 2006; 80: 2797-807
|
|
|
|
|
|
12) Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001; 7: 927-33
|
|
|
|
|
|
13) Suzuki F, Tsubota A, Arase Y, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology. 2003; 46: 182-9
|
|
|
|
|
|
14) Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999; 30: 567-72
|
|
|
|
|
|
15) Yatsuji H, Noguchi C, Hiraga N, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother. 2006; 50: 3867-74
|
|
|
|
|
|
16) Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genoptypes on the intra and extracellular expression of viral DNA and antigens. Hepatology. 2006; 44: 915-24
|
|
|
|
|
|
17) Sugiyama M, Tanaka Y, Sakamoto T, et al. Early dynamics od hepatitis B virus in chimeric mice carting human hepatocytes monoinfected or coinfected with genotype G. Hepatology. 2007; 45: 929-37
|
|
|
|
|